TN2010000137A1 - Spiropyrrolidines and their use against hcv and hiv infection - Google Patents

Spiropyrrolidines and their use against hcv and hiv infection

Info

Publication number
TN2010000137A1
TN2010000137A1 TNP2010000137A TN2010000137A TN2010000137A1 TN 2010000137 A1 TN2010000137 A1 TN 2010000137A1 TN P2010000137 A TNP2010000137 A TN P2010000137A TN 2010000137 A TN2010000137 A TN 2010000137A TN 2010000137 A1 TN2010000137 A1 TN 2010000137A1
Authority
TN
Tunisia
Prior art keywords
spiropyrrolidines
hiv infection
use against
against hcv
hcv
Prior art date
Application number
TNP2010000137A
Other languages
English (en)
Inventor
Shawn D Britt
Lech Andrzej Ciszewski
Jiping Fu
Subramanian Karur
Yugang Liu
David Thomas Parker
Mahavir Prashad
Prakash Raman
Saud Mohindra Seeper
Rui Zheng
Peichao Lu
Pascal Rigollier
Aregahegn Yifru
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2010000137A1 publication Critical patent/TN2010000137A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TNP2010000137A 2007-10-10 2010-03-26 Spiropyrrolidines and their use against hcv and hiv infection TN2010000137A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97897407P 2007-10-10 2007-10-10
PCT/EP2008/063460 WO2009047264A1 (fr) 2007-10-10 2008-10-08 Composés organiques et leurs utilisations

Publications (1)

Publication Number Publication Date
TN2010000137A1 true TN2010000137A1 (en) 2011-09-26

Family

ID=40243948

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000137A TN2010000137A1 (en) 2007-10-10 2010-03-26 Spiropyrrolidines and their use against hcv and hiv infection

Country Status (20)

Country Link
US (2) US8008263B2 (fr)
EP (1) EP2205584A1 (fr)
JP (1) JP5095824B2 (fr)
KR (2) KR101396696B1 (fr)
CN (2) CN104016970A (fr)
AR (1) AR068756A1 (fr)
AU (1) AU2008309589B2 (fr)
BR (1) BRPI0817881A2 (fr)
CA (1) CA2702132A1 (fr)
CL (1) CL2008002995A1 (fr)
CO (1) CO6270317A2 (fr)
CR (1) CR11310A (fr)
EA (1) EA020951B1 (fr)
MA (1) MA31767B1 (fr)
MX (1) MX2010003916A (fr)
PE (1) PE20091237A1 (fr)
TN (1) TN2010000137A1 (fr)
TW (1) TW200932737A (fr)
WO (1) WO2009047264A1 (fr)
ZA (1) ZA201001585B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571826A (en) * 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
US8309685B2 (en) 2007-12-21 2012-11-13 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
NZ586232A (en) 2007-12-21 2012-12-21 Avila Therapeutics Inc HCV protease inhibitors comprising a functionalised proline derivative
AU2008340257B2 (en) 2007-12-21 2015-06-11 Celgene Avilomics Research, Inc. HCV protease inhibitors and uses thereof
JP2012505897A (ja) * 2008-10-15 2012-03-08 インターミューン・インコーポレーテッド 治療用抗ウイルス性ペプチド
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
KR20130026410A (en) * 2009-09-28 2013-03-13 Intermune Inc Cyclic peptide inhibitors of hepatitis c virus replication
TW201116540A (en) * 2009-10-01 2011-05-16 Intermune Inc Therapeutic antiviral peptides
KR20130120481A (ko) * 2010-10-08 2013-11-04 노파르티스 아게 술파미드 ｎｓ3 억제제의 비타민 ｅ 제제
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013030750A1 (fr) 2011-09-01 2013-03-07 Lupin Limited Composés antiviraux
CA2862755A1 (fr) 2012-02-10 2013-08-15 Lupin Limited Composes antiviraux avec une fraction dibenzooxaheterocycle
CN103420991B (zh) * 2012-05-17 2017-07-07 乳源东阳光药业有限公司 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用
TW201408669A (zh) * 2012-08-08 2014-03-01 Merck Sharp & Dohme Ｈｃｖ ｎｓ３蛋白酶抑制劑
TW201412709A (zh) 2012-09-28 2014-04-01 Sunshine Lake Pharma Co Ltd 作為丙型肝炎抑制劑的螺環化合物及其在藥物中的應用
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
EP2914613B1 (fr) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014070974A1 (fr) 2012-11-05 2014-05-08 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN103848819B (zh) * 2012-11-29 2017-04-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们在药物中的应用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
EP2964664B1 (fr) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Inhibiteurs du virus de l'hépatite c
JP6431038B2 (ja) 2013-03-15 2018-11-28 ザイムワークス インコーポレイティド 細胞毒性及び抗有糸分裂性化合物とその使用方法
US11560422B2 (en) 2013-12-27 2023-01-24 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
CA2935064C (fr) 2013-12-27 2023-06-27 Zymeworks Inc. Conjugues var2csa-medicament
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
PT3194421T (pt) 2014-09-17 2022-02-07 Zymeworks Inc Compostos citotóxicos e antimitóticos e métodos de uso dos mesmos
US11234977B2 (en) 2017-12-20 2022-02-01 Novartis Ag Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
MX2023005983A (es) 2020-11-23 2023-08-15 Enanta Pharm Inc Nuevos agentes antivirales derivados de la espiropirrolidina.
US20240051950A1 (en) * 2020-12-22 2024-02-15 The Regents Of The University Of California Novel CYP3A4-Specific Inhibitors and Methods of Using Same
US11970502B2 (en) 2021-05-04 2024-04-30 Enanta Pharmaceuticals, Inc. Macrocyclic antiviral agents
WO2023003610A1 (fr) * 2021-07-23 2023-01-26 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
WO2023086352A1 (fr) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Nouveaux agents antiviraux dérivés de spiropyrrolidine
WO2023086350A1 (fr) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Agents antiviraux contenant des alcynes
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
BR0112540A (pt) * 2000-07-21 2003-06-24 Schering Corp Peptìdios como inibidores da ns-3-serina protease do vìrus da hepatite c
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
PE20030857A1 (es) 2002-01-23 2003-10-25 Schering Corp Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
US7309717B2 (en) * 2003-06-17 2007-12-18 Schering Corporation Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof
EP1664090A2 (fr) * 2003-08-26 2006-06-07 Schering Corporation Nouveaux inhibiteurs peptidomimetiques de la serine protease ns3 du virus de l'hepatite c
TWI359147B (en) * 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20050119189A1 (en) * 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PT1677827E (pt) * 2003-10-27 2009-03-13 Vertex Pharma Associações para o tratamento do vhc
RU2006124594A (ru) * 2003-12-11 2008-01-27 Шеринг Корпорейшн (US) Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с
AU2005212257A1 (en) * 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
RU2006134005A (ru) * 2004-02-27 2008-04-10 Шеринг Корпорейшн (US) Новые соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
CA2557304C (fr) * 2004-02-27 2013-08-06 Schering Corporation Nouveaux cetoamides a p4 cycliques en tant qu'inhibiteurs de la ns3 serine protease du virus de l'hepatite c
JP4745327B2 (ja) * 2004-02-27 2011-08-10 シェーリング コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
CA2557495C (fr) * 2004-02-27 2014-04-15 Schering Corporation Composes soufres en tant qu'inhibiteurs de la protease serine ns3 du virus de l'hepatite c
JP2007525512A (ja) * 2004-02-27 2007-09-06 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３セリンプロテアーゼのインヒビターとしての３，４−（シクロペンチル）−縮合プロリン化合物
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
TWI389688B (zh) * 2004-06-08 2013-03-21 Vertex Pharma Vx-950之形態與調配物及其製備方法與用途
WO2006026352A1 (fr) * 2004-08-27 2006-03-09 Schering Corporation Composes d'acylsulfonamide inhibiteurs de la serine protease ns3 du virus de l'hepatite c
US7250441B2 (en) * 2004-09-23 2007-07-31 Wyeth Carbazole and cyclopentaindole derivatives to treat infection with Hepatitis C virus
EP1804821A4 (fr) * 2004-10-01 2009-07-15 Vertex Pharma Inhibition de la protease ns3-ns4a du vhc
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
US20070004635A1 (en) * 2005-06-02 2007-01-04 Schering Corporation Method of treating interferon non-responders using HCV protease inhibitor
EP1891089B1 (fr) * 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. Inhibiteurs de protease du VHC en combinaison avec des aliments
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
WO2006130626A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Procede de modulation de l'activite de la protease du vhc au moyen d'un nouvel inhibiteur de la protease du vhc aux fins de la reduction de la duree du traitement
WO2006130687A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Taux de concentration foie/plasma pour le dosage de l'inhibiteur de protease du virus de l'hepatite c
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
JP2009505966A (ja) * 2005-08-02 2009-02-12 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼのインヒビター
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
WO2007120595A2 (fr) * 2006-04-11 2007-10-25 Novartis Ag Composés organiques et leurs utilisations
AU2007238252A1 (en) * 2006-04-11 2007-10-25 Novartis Ag HCV inhibitors comprising beta amino acids and their uses
KR20080104366A (ko) * 2006-04-11 2008-12-02 노파르티스 아게 Ｈｃｖ 억제제
NZ571826A (en) * 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
WO2008059367A1 (fr) 2006-11-14 2008-05-22 Pfizer Products Inc. Promédicaments de sulopénème
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
CL2008000017A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
JP5591706B2 (ja) 2007-10-10 2014-09-17 アムジエン・インコーポレーテツド 置換ビフェニルｇｐｒ４０調節因子
TW200924778A (en) 2007-10-10 2009-06-16 Takeda Pharmaceutical Amide compound
UA100527C2 (en) 2007-10-10 2013-01-10 Астразенека Аб Benzothiazoles as ghrelin receptor modulators

Also Published As

Publication number Publication date
KR101396696B1 (ko) 2014-05-16
CO6270317A2 (es) 2011-04-20
AU2008309589B2 (en) 2012-07-05
CL2008002995A1 (es) 2009-06-26
AR068756A1 (es) 2009-12-02
US8222425B2 (en) 2012-07-17
CR11310A (es) 2010-05-06
JP2011500528A (ja) 2011-01-06
KR101218882B1 (ko) 2013-01-07
MX2010003916A (es) 2010-05-05
CN104016970A (zh) 2014-09-03
EA201000556A1 (ru) 2010-10-29
ZA201001585B (en) 2010-12-29
JP5095824B2 (ja) 2012-12-12
CN101868452A (zh) 2010-10-20
BRPI0817881A2 (pt) 2015-03-31
MA31767B1 (fr) 2010-10-01
AU2008309589A1 (en) 2009-04-16
WO2009047264A1 (fr) 2009-04-16
KR20120094049A (ko) 2012-08-23
CA2702132A1 (fr) 2009-04-16
TW200932737A (en) 2009-08-01
US8008263B2 (en) 2011-08-30
PE20091237A1 (es) 2009-09-14
US20110275819A1 (en) 2011-11-10
US20090137495A1 (en) 2009-05-28
CN101868452B (zh) 2014-08-06
EA020951B1 (ru) 2015-03-31
KR20100051749A (ko) 2010-05-17
EP2205584A1 (fr) 2010-07-14

Similar Documents

Publication Publication Date Title
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
TNSN08400A1 (en) Organic compounds and their uses
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TN2011000482A1 (en) Organic compounds and their uses
EA201100505A1 (ru) Органические соединения для применения для лечения бактериальных инфекций
WO2007121125A3 (fr) Composés organiques et leurs utilisations
MX2009011002A (es) Composiciones de proteccion de isquemia/reperfusion y metodos de uso.
EP2493464A4 (fr) Méthylsulfonylméthane (msm) pour le traitement de micro-organismes résistants aux médicaments
WO2010002877A3 (fr) Nucléosides bicycliques et nucléotides convenant comme agents thérapeutiques
WO2008127364A3 (fr) Composés antiviraux et utilisation de ceux-ci
MY161495A (en) Virus like particle compositions and methods of use
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
IN2012DN00624A (fr)
WO2007121124A3 (fr) Composés organiques et leurs utilisations
EP2192901A4 (fr) Agents chimiques, compositions et procédés de traitement et de prévention des infections à orthopoxvirus et des maladies associées
TNSN08496A1 (en) Aminothiazoles and their uses
TN2011000204A1 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
WO2010074936A3 (fr) Enzastaurine dans le traitement du cancer
EP2224943A4 (fr) Utilisation d'un anticorps humain pouvant neutrdaliser le virus de l'hépatite b pour la prévention ou le traitement d'une infection par ledit virus
AR053775A1 (es) Nonadepsipeptidos acilados ii
WO2008033389A3 (fr) Composés organiques et leurs utilisations
WO2007076091A3 (fr) Traitement d’infections virales utilisant un inhibiteur de facteur tissulaire
TN2009000495A1 (en) Macrocycles and their uses
MX2013003903A (es) Nuevos tratamientos de infeccion por el virus de hepatitis c.
GT201000166A (es) Aminotiazoles y sus usos